Beckman Coulter, Inc. is currently one of the world’s strongest manufacturers of equipment, reagents, and application software in the field of experimental medicine. In the past 100 years, Beckman Coulter  has been committed to the research and development of top-level medical equipment, and has successively introduced advanced equipment and technologies such as blood cell analysis systems, immunodiagnostic systems, centrifuges, rapid test kits, and Beckman detectors, which have made incalculable contributions to the development of human medicine.

Realcan is a company that sells drugs, medical devices, and medical consumables to medical institutions nationwide. It also has eight major service sectors including financial technology, traditional Chinese medicine, digital medicine, pharmaceutical science, professional logistics, device R&D and production, medical diagnosis, and device integration medical service provider.In 2019, the operating income of the medical device sector reached 35.259 billion yuan, among which the operating income of the medical device sector reached 13.664 billion yuan, second only to Sinopharm Holding, ranking the second in the industry, and it’s one of the leading enterprises in the pharmaceutical and medical device circulation industry in China.

After this strategic cooperation is reached, Beckman Coulter's full range of products will be fully open to Realcan. Both parties will carry out more in-depth cooperation in the field of medical diagnosis, further enhance consensus, give play to their respective advantages, achieve win-win results, and jointly promote the development of the medical and health industry.